Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26748819 | 0.86 | ACACB (0.54) | ACACBGPR119 | |
| SCHEMBL18591817 | 0.85 | EGLN2 (0.40) | ACACBEGLN2P4HTMGPR119 | |
| SCHEMBL19606450 | 0.85 | ACACB (0.48) | ACACBGPR119 | |
| SCHEMBL20812324 | 0.81 | EGLN2 (0.38) | ACACBEGLN2P4HTMGPR119 | |
| SCHEMBL19959072 | 0.80 | EGLN2 (0.42) | ACACBEGLN2P4HTMGPR119 | |
| SCHEMBL20805438 | 0.78 | HRH3 (0.41) | ACACB | |
| SCHEMBL26748822 | 0.76 | PANK3 (0.44) | GPR119 | |
| SCHEMBL22019296 | 0.74 | TLR9 (0.35) | — | |
| SCHEMBL20133096 | 0.74 | CHRNB2 (0.36) | ACACB | |
| SCHEMBL24654370 | 0.73 | ACACB (0.48) | ACACBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ACACB 760/4885EGLN2 170/4885P4HTM 446/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | ACACB 3370/4885EGLN2 394/4885P4HTM 1059/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | ACACB 3951/4885EGLN2 255/4885P4HTM 1420/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | ACACB 3370/4885EGLN2 394/4885P4HTM 1059/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ACACB 760/4885EGLN2 170/4885P4HTM 446/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | ACACB 3951/4885EGLN2 255/4885P4HTM 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.